Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tobias J. O'Neill"'
Autor:
Mary E. Klotman, Paul J. Maddon, Alexandra Trkola, Jeffrey M. Jacobson, Tobias J. O'Neill, Robert J. Israel, William C. Olson, Thomas J. Ketas, Israel Lowy, Courtney V. Fletcher, Diep N. H. Tran
Publikováno v:
The Journal of Infectious Diseases. 182:326-329
PRO 542 (CD4-IgG2) is a recombinant antibody-like fusion protein wherein the Fv portions of both the heavy and light chains of human IgG2 have been replaced with the D1D2 domains of human CD4. Unlike monovalent and divalent CD4-based proteins, tetrav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc345f068f024b306dc2122adff85bbd
https://doi.org/10.1086/315698
https://doi.org/10.1086/315698
Autor:
Nancy A. Ostrow, Linda S. Vassilatos, William C. Olson, Wei Huang, Diep N. H. Tran, Robert J. Israel, Jeffrey M. Jacobson, Paul J. Maddon, Brian M. Sullivan, Melanie Barish, Thomas J. Ketas, Tobias J. O'Neill, Kirsten A. Nagashima, Christos J. Petropoulos, Israel Lowy, John P. Moore
Publikováno v:
Antimicrobial agents and chemotherapy. 48(2)
Viral entry inhibitors represent an emerging mode of therapy for human immunodeficiency virus type 1 (HIV-1) infection. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0a02446bd3b8743467eb7663f6d39ea
https://pubmed.ncbi.nlm.nih.gov/14742190
https://pubmed.ncbi.nlm.nih.gov/14742190